Research programme: ddRNAi therapeutics - Benitec Biopharma

Drug Profile

Research programme: ddRNAi therapeutics - Benitec Biopharma

Alternative Names: BB 501; Research programme: ddRNAi therapeutics

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Benitec Biopharma
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • Research Head and neck cancer

Most Recent Events

  • 03 Feb 2017 Early research in Head and neck cancer in USA (unspecified route) before February 2017 (Benitec Biopharma pipeline, February 2017)
  • 03 Feb 2017 Preclinical trials in Solid tumours in USA (unspecified route) before February 2017
  • 24 Oct 2016 Benitec Biopharma and NantWorks enter a collaboration agreement to lead the preclinical development in USA for Solid tumours and Head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top